Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection
In solid organ transplant recipients, serious adverse reactions have been associated with the initial doses of Orthoclone OKT3. Most patients receiving OKT3 report a "flu-like" syndrome, characterized by fever, chills, nausea, vomiting, and headache. There is evidence from both in vitro an...
Gespeichert in:
| Veröffentlicht in: | Transplantation 1992-07, Vol.54 (1), p.164-166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 1 |
| container_start_page | 164 |
| container_title | Transplantation |
| container_volume | 54 |
| creator | SHIELD, C. F KAHANA, L DINARELLO, C. A DEHLINGER, J SHU-CHEN H. WU VAN HORN, A PIRSCH, J VERNGE-MARINI, P FIRST, M. R SCHROEDER, T. J COHEN, D NORMAN, D. J MONACO, A MAERTINEZ, A |
| description | In solid organ transplant recipients, serious adverse reactions have been associated with the initial doses of Orthoclone OKT3. Most patients receiving OKT3 report a "flu-like" syndrome, characterized by fever, chills, nausea, vomiting, and headache. There is evidence from both in vitro and in vivo studies of an association between cytokine release and the systemic reactions noted during the initial 24-48 hr of OKT3 therapy. Inhibition of cytokine release by the use of cyclooxygenase inhibitors has been reported to modify the symptom complex exhibited in both animals and humans. These results prompted the design of a randomized, placebo-controlled, multicenter study to evaluate the effects of the cyclooxygenase inhibitor, indomethacin, during the first 48 hr of OKT3 therapy on the incidence and severity of first-dose reactions and the expression of cytokines in patients undergoing acute renal allograft rejection. |
| doi_str_mv | 10.1097/00007890-199207000-00030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73065034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73065034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-790a0795ad4f40392eaacdd1e7afec66d6dcf4650fafa87b69f11fc6bf0958c23</originalsourceid><addsrcrecordid>eNqFkdFqFDEUhoNY6tr2EYRciHejJ5OZZHIpRVux0Jv2ejibnLipM5OaZJUKvrvZ7lovGwghnO__A_kY4wLeCzD6A9SlBwONMKYFXW9N3RJesJXoZdcoGOAlWwF0ohFS6lfsdc53Feml1sfsWCgpTKtX7M9tJh49D4uLM5UN2rDwEvkcljCH38TLhji6n5QqlwhtCXHJHHOONmAhx3-FsuExlU20U1yIX3-9kbxUtMy0lF339-AWeuA4TfFbQl9qzx09Fp2yI49TprPDecJuP3-6Ob9srq4vvpx_vGps10JptAEEbXp0ne9AmpYQrXOCNHqySjnlrO9UDx49DnqtjBfCW7X2YPrBtvKEvdv33qf4Y0u5jHPIlqYJF4rbPGoJNS27Z0GhetnKftc47EGbYs6J_HifwozpYRQw7hSN_xSNT4rGR0U1-ubwxnY9k_sf3Dup87eHOWaLk0-42JCfsE7q-gVG_gWOM5up</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16532352</pqid></control><display><type>article</type><title>Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>SHIELD, C. F ; KAHANA, L ; DINARELLO, C. A ; DEHLINGER, J ; SHU-CHEN H. WU ; VAN HORN, A ; PIRSCH, J ; VERNGE-MARINI, P ; FIRST, M. R ; SCHROEDER, T. J ; COHEN, D ; NORMAN, D. J ; MONACO, A ; MAERTINEZ, A</creator><creatorcontrib>SHIELD, C. F ; KAHANA, L ; DINARELLO, C. A ; DEHLINGER, J ; SHU-CHEN H. WU ; VAN HORN, A ; PIRSCH, J ; VERNGE-MARINI, P ; FIRST, M. R ; SCHROEDER, T. J ; COHEN, D ; NORMAN, D. J ; MONACO, A ; MAERTINEZ, A</creatorcontrib><description>In solid organ transplant recipients, serious adverse reactions have been associated with the initial doses of Orthoclone OKT3. Most patients receiving OKT3 report a "flu-like" syndrome, characterized by fever, chills, nausea, vomiting, and headache. There is evidence from both in vitro and in vivo studies of an association between cytokine release and the systemic reactions noted during the initial 24-48 hr of OKT3 therapy. Inhibition of cytokine release by the use of cyclooxygenase inhibitors has been reported to modify the symptom complex exhibited in both animals and humans. These results prompted the design of a randomized, placebo-controlled, multicenter study to evaluate the effects of the cyclooxygenase inhibitor, indomethacin, during the first 48 hr of OKT3 therapy on the incidence and severity of first-dose reactions and the expression of cytokines in patients undergoing acute renal allograft rejection.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-199207000-00030</identifier><identifier>PMID: 1631927</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adult ; Biological and medical sciences ; Cytokines - biosynthesis ; Female ; Graft Rejection ; Humans ; Immunomodulators ; Indomethacin - therapeutic use ; Kidney Transplantation - adverse effects ; Male ; Medical sciences ; Middle Aged ; Muromonab-CD3 - adverse effects ; Pharmacology. Drug treatments ; Transplantation, Homologous</subject><ispartof>Transplantation, 1992-07, Vol.54 (1), p.164-166</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-790a0795ad4f40392eaacdd1e7afec66d6dcf4650fafa87b69f11fc6bf0958c23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4370399$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1631927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIELD, C. F</creatorcontrib><creatorcontrib>KAHANA, L</creatorcontrib><creatorcontrib>DINARELLO, C. A</creatorcontrib><creatorcontrib>DEHLINGER, J</creatorcontrib><creatorcontrib>SHU-CHEN H. WU</creatorcontrib><creatorcontrib>VAN HORN, A</creatorcontrib><creatorcontrib>PIRSCH, J</creatorcontrib><creatorcontrib>VERNGE-MARINI, P</creatorcontrib><creatorcontrib>FIRST, M. R</creatorcontrib><creatorcontrib>SCHROEDER, T. J</creatorcontrib><creatorcontrib>COHEN, D</creatorcontrib><creatorcontrib>NORMAN, D. J</creatorcontrib><creatorcontrib>MONACO, A</creatorcontrib><creatorcontrib>MAERTINEZ, A</creatorcontrib><title>Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>In solid organ transplant recipients, serious adverse reactions have been associated with the initial doses of Orthoclone OKT3. Most patients receiving OKT3 report a "flu-like" syndrome, characterized by fever, chills, nausea, vomiting, and headache. There is evidence from both in vitro and in vivo studies of an association between cytokine release and the systemic reactions noted during the initial 24-48 hr of OKT3 therapy. Inhibition of cytokine release by the use of cyclooxygenase inhibitors has been reported to modify the symptom complex exhibited in both animals and humans. These results prompted the design of a randomized, placebo-controlled, multicenter study to evaluate the effects of the cyclooxygenase inhibitor, indomethacin, during the first 48 hr of OKT3 therapy on the incidence and severity of first-dose reactions and the expression of cytokines in patients undergoing acute renal allograft rejection.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cytokines - biosynthesis</subject><subject>Female</subject><subject>Graft Rejection</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Indomethacin - therapeutic use</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muromonab-CD3 - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Transplantation, Homologous</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkdFqFDEUhoNY6tr2EYRciHejJ5OZZHIpRVux0Jv2ejibnLipM5OaZJUKvrvZ7lovGwghnO__A_kY4wLeCzD6A9SlBwONMKYFXW9N3RJesJXoZdcoGOAlWwF0ohFS6lfsdc53Feml1sfsWCgpTKtX7M9tJh49D4uLM5UN2rDwEvkcljCH38TLhji6n5QqlwhtCXHJHHOONmAhx3-FsuExlU20U1yIX3-9kbxUtMy0lF339-AWeuA4TfFbQl9qzx09Fp2yI49TprPDecJuP3-6Ob9srq4vvpx_vGps10JptAEEbXp0ne9AmpYQrXOCNHqySjnlrO9UDx49DnqtjBfCW7X2YPrBtvKEvdv33qf4Y0u5jHPIlqYJF4rbPGoJNS27Z0GhetnKftc47EGbYs6J_HifwozpYRQw7hSN_xSNT4rGR0U1-ubwxnY9k_sf3Dup87eHOWaLk0-42JCfsE7q-gVG_gWOM5up</recordid><startdate>19920701</startdate><enddate>19920701</enddate><creator>SHIELD, C. F</creator><creator>KAHANA, L</creator><creator>DINARELLO, C. A</creator><creator>DEHLINGER, J</creator><creator>SHU-CHEN H. WU</creator><creator>VAN HORN, A</creator><creator>PIRSCH, J</creator><creator>VERNGE-MARINI, P</creator><creator>FIRST, M. R</creator><creator>SCHROEDER, T. J</creator><creator>COHEN, D</creator><creator>NORMAN, D. J</creator><creator>MONACO, A</creator><creator>MAERTINEZ, A</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19920701</creationdate><title>Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection</title><author>SHIELD, C. F ; KAHANA, L ; DINARELLO, C. A ; DEHLINGER, J ; SHU-CHEN H. WU ; VAN HORN, A ; PIRSCH, J ; VERNGE-MARINI, P ; FIRST, M. R ; SCHROEDER, T. J ; COHEN, D ; NORMAN, D. J ; MONACO, A ; MAERTINEZ, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-790a0795ad4f40392eaacdd1e7afec66d6dcf4650fafa87b69f11fc6bf0958c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cytokines - biosynthesis</topic><topic>Female</topic><topic>Graft Rejection</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Indomethacin - therapeutic use</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muromonab-CD3 - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHIELD, C. F</creatorcontrib><creatorcontrib>KAHANA, L</creatorcontrib><creatorcontrib>DINARELLO, C. A</creatorcontrib><creatorcontrib>DEHLINGER, J</creatorcontrib><creatorcontrib>SHU-CHEN H. WU</creatorcontrib><creatorcontrib>VAN HORN, A</creatorcontrib><creatorcontrib>PIRSCH, J</creatorcontrib><creatorcontrib>VERNGE-MARINI, P</creatorcontrib><creatorcontrib>FIRST, M. R</creatorcontrib><creatorcontrib>SCHROEDER, T. J</creatorcontrib><creatorcontrib>COHEN, D</creatorcontrib><creatorcontrib>NORMAN, D. J</creatorcontrib><creatorcontrib>MONACO, A</creatorcontrib><creatorcontrib>MAERTINEZ, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIELD, C. F</au><au>KAHANA, L</au><au>DINARELLO, C. A</au><au>DEHLINGER, J</au><au>SHU-CHEN H. WU</au><au>VAN HORN, A</au><au>PIRSCH, J</au><au>VERNGE-MARINI, P</au><au>FIRST, M. R</au><au>SCHROEDER, T. J</au><au>COHEN, D</au><au>NORMAN, D. J</au><au>MONACO, A</au><au>MAERTINEZ, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1992-07-01</date><risdate>1992</risdate><volume>54</volume><issue>1</issue><spage>164</spage><epage>166</epage><pages>164-166</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>In solid organ transplant recipients, serious adverse reactions have been associated with the initial doses of Orthoclone OKT3. Most patients receiving OKT3 report a "flu-like" syndrome, characterized by fever, chills, nausea, vomiting, and headache. There is evidence from both in vitro and in vivo studies of an association between cytokine release and the systemic reactions noted during the initial 24-48 hr of OKT3 therapy. Inhibition of cytokine release by the use of cyclooxygenase inhibitors has been reported to modify the symptom complex exhibited in both animals and humans. These results prompted the design of a randomized, placebo-controlled, multicenter study to evaluate the effects of the cyclooxygenase inhibitor, indomethacin, during the first 48 hr of OKT3 therapy on the incidence and severity of first-dose reactions and the expression of cytokines in patients undergoing acute renal allograft rejection.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>1631927</pmid><doi>10.1097/00007890-199207000-00030</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 1992-07, Vol.54 (1), p.164-166 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73065034 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Biological and medical sciences Cytokines - biosynthesis Female Graft Rejection Humans Immunomodulators Indomethacin - therapeutic use Kidney Transplantation - adverse effects Male Medical sciences Middle Aged Muromonab-CD3 - adverse effects Pharmacology. Drug treatments Transplantation, Homologous |
| title | Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20indomethacin%20to%20minimize%20the%20adverse%20reactions%20associated%20with%20orthoclone%20OKT3%20treatment%20of%20kidney%20allograft%20rejection&rft.jtitle=Transplantation&rft.au=SHIELD,%20C.%20F&rft.date=1992-07-01&rft.volume=54&rft.issue=1&rft.spage=164&rft.epage=166&rft.pages=164-166&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-199207000-00030&rft_dat=%3Cproquest_cross%3E73065034%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16532352&rft_id=info:pmid/1631927&rfr_iscdi=true |